Alphanine SD Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established treatment for hemophilia b, plasma derived factor availability, hospital reliance on factor replacement, surgical bleeding management needs, clinical efficacy in bleed control.

The growth in the forecast period can be attributed to growing hemophilia diagnosis rates, expansion of prophylactic therapy use, increasing surgical interventions, stable plasma supply, demand in emerging healthcare markets. Major trends in the forecast period include continued use of plasma derived clotting factors, demand for hemophilia b prophylaxis, hospital based bleeding management, preference for high purity factor IX, use in surgical bleeding control.

The increasing prevalence of hemophilia is expected to drive the growth of the Alphanine SD market in the coming years. Hemophilia is a rare inherited bleeding disorder in which the blood fails to clot properly due to a deficiency or absence of clotting factors such as factor VIII or factor IX. The rising prevalence of hemophilia is influenced by improved diagnostic capabilities, greater awareness initiatives, enhanced healthcare infrastructure, and increased life expectancy resulting from advances in treatment. Alphanine SD supports the management of hemophilia B by providing targeted therapy that helps control bleeding episodes and improve patient outcomes, particularly as better diagnosis, reporting, and awareness contribute to a growing number of identified cases. For instance, in October 2025, according to a report published by the World Federation of Hemophilia (WFH), as of 2024 there were 271,918 identified patients with hemophilia worldwide, including 224,353 individuals with hemophilia A and 45,600 with hemophilia B. Therefore, the growing prevalence of hemophilia is driving the Alphanine SD market.

The expanding aging population is expected to further support the growth of the Alphanine SD market. The aging population refers to the increasing proportion of individuals aged 65 years and older, primarily resulting from longer life expectancy and declining birth rates. This demographic shift is driven by advances in healthcare, medical technologies, improved living standards, and better disease management. Alphanine SD is particularly important for the aging population, as it provides effective treatment for bleeding disorders, helping to manage clotting-related complications in older adults. This supports improved health outcomes, enhances quality of life, and reduces the risk of complications associated with hemophilia and clotting deficiencies, allowing older individuals to maintain greater independence. For instance, in October 2025, according to the World Health Organization, it is projected that by 2030, one in six people globally will be aged 60 years or older, and by 2050, the global population aged 60 years and above will double to 2.1 billion. Therefore, the rising aging population is driving the Alphanine SD market.

The increase in healthcare expenditure is also expected to propel the growth of the Alphanine SD market. Healthcare expenditure refers to the total financial resources allocated toward medical services, healthcare infrastructure, pharmaceuticals, and related healthcare activities. Rising healthcare spending is driven by factors such as population aging, the growing burden of chronic and lifestyle-related diseases, advances in medical technology, and improved access to healthcare services. Alphanine SD contributes to healthcare expenditure due to costs associated with its long-term prophylactic use, management of bleeding episodes, and the need for ongoing clinical care in hemophilia B patients. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare expenditure increased by 5.6% in nominal terms between 2022 and 2023, compared with growth of 0.9% in 2022. Therefore, the rise in healthcare expenditure is driving the growth of the Alphanine SD market.

Major companies operating in the alphanine sd market are Grifols SA.

North America was the largest region in the alphanine SD market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the alphanine sd market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the alphanine sd market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the alphanine sd market by increasing the cost of imported plasma fractionation equipment, sterile vials, and cold chain logistics used in factor ix production and distribution. These effects have been most pronounced in north america and europe, where plasma derived therapies are widely manufactured and utilized. Hospitals and hemophilia treatment centers have faced higher procurement costs for lyophilized and intravenous factor ix products. However, tariffs have also encouraged domestic plasma processing and clotting factor manufacturing, strengthening local supply chains and improving long term treatment availability.

The alphanine sd market research report is one of a series of new reports that provides alphanine sd market statistics, including alphanine sd industry global market size, regional shares, competitors with a alphanine sd market share, detailed alphanine sd market segments, market trends and opportunities, and any further data you may need to thrive in the alphanine sd industry. This alphanine sd market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Alphanine SD is a high-purity, freeze-dried Factor IX concentrate obtained from human plasma and is specifically developed to treat hemophilia B by replacing the missing clotting factor. It is used to prevent and control bleeding episodes, manage bleeding during surgical procedures, and provide routine prophylactic care for individuals with hemophilia B.

The main product types in the Alphanine SD market include plasma-derived factor IX concentrates and recombinant factor IX products. Plasma-derived factor IX concentrates are highly purified products sourced from human plasma and are used to treat factor IX deficiencies. In the Alphanine SD market, these products effectively support the management and treatment of bleeding disorders such as hemophilia B. They are available in formulations including lyophilized powder and intravenous solutions. The clinical indications include hemophilia B, inhibitor management, bleeding episodes, and surgical prophylaxis, and the therapy is intended for use in adult, pediatric, and geriatric patients.

The alphanine SD market consists of sales of infusion devices, dilution kits, and prophylactic products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.